This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ettinger, S. L. Articles by Nelson, C. C. Search for Related Content PubMed PubMed Citation Articles by Ettinger, S. L. Articles by Nelson, C. C.

Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence

The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada

Androgen ablation, the most common therapeutic treatment used for advanced prostate cancer, triggers the apoptotic regression of prostate tumors. However, remissions are temporary because surviving prostate cancer cells adapt to the androgen-deprived environment and form androgen-independent (AI) tumors. We hypothesize that adaptive responses of surviving tumor cells result from dysregulated gene expression of key cell survival pathways. Therefore, we examined temporal alterations to gene expression profiles in prostate cancer during progression to androgen independence at several time points using the LNCaP xenograft tumor model. Two key genes, sterol response element-binding protein (SREBP)-1 and -2 (SREBP-1a,-1c, and -2), were consistently dysregulated. These genes are known to coordinately control the expression of the groups of enzymes responsible for lipid and cholesterol synthesis. Northern blots revealed modest increased expression of SREBP-1a, -1c, and -2 after castration, and at androgen independence (day 21–28), the expression levels of both SREBP-1a and -1c were significantly greater than precastrate levels. Changes in SREBP-1 and -2 protein expression were observed by Western analysis. SREBP-1 68-kDa protein levels were maintained throughout progression, however, SREBP-2 68-kDa protein expression increased after castration and during progression (3-fold). SREBPs are transcriptional regulators of over 20 functionally related enzymes that coordinately control the metabolic pathways of lipogenesis and cholesterol synthesis, some of which were likewise dysregulated during progression to androgen independence. RNA levels of acyl-CoA-binding protein/diazepam-binding inhibitor and fatty acid synthase decreased significantly after castration, and then, during progression, increased to levels greater than or equal to precastrate levels. Expression of farnesyl diphosphate synthase did not decrease after castration but did increase significantly during progression to androgen independence. Levels of SREBP cleavage-activating protein, a regulator of SREBP transcriptional activity, decreased after castration and increased significantly at androgen independence. In clinical prostate cancer specimens from patients with varying grades of disease, the stained tissue sections showed high levels of SREBP-1 protein compared with noncancerous prostate tissue. After hormone withdrawal therapy, tumor levels of SREBP-1 decreased significantly after 6 weeks. AI tumors expressed significantly higher levels of SREBP-1. In summary, the LNCaP xenograft model of human prostate cancer as well as clinical specimens of prostate cancer demonstrated an up-regulation of SREBPs and their downstream effector genes during progression to androgen independence. As the AI phenotype emerges, enzymes critical for lipogenesis and cholesterol synthesis are activated and likely contribute significantly to cell survival of AI prostate cancer.

This article has been cited by other articles:

				J. A. Locke, E. S. Guns, A. A. Lubik, H. H. Adomat, S. C. Hendy, C. A. Wood, S. L. Ettinger, M. E. Gleave, and C. C. Nelson Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer Cancer Res., August 1, 2008; 68(15): 6407 - 6415. [Abstract] [Full Text] [PDF]

				D. R. Cochrane, Z. Wang, M. Muramaki, M. E. Gleave, and C. C. Nelson Differential Regulation of Clusterin and Its Isoforms by Androgens in Prostate Cells J. Biol. Chem., January 26, 2007; 282(4): 2278 - 2287. [Abstract] [Full Text] [PDF]

				H. Cheng, R. Snoek, F. Ghaidi, M. E. Cox, and P. S. Rennie Short Hairpin RNA Knockdown of the Androgen Receptor Attenuates Ligand-Independent Activation and Delays Tumor Progression Cancer Res., November 1, 2006; 66(21): 10613 - 10620. [Abstract] [Full Text] [PDF]

				H. V. Heemers, G. Verhoeven, and J. V. Swinnen Androgen Activation of the Sterol Regulatory Element-Binding Protein Pathway: Current Insights Mol. Endocrinol., October 1, 2006; 20(10): 2265 - 2277. [Abstract] [Full Text] [PDF]

				L. A. Meza-Zepeda, S. H. Kresse, A. H. Barragan-Polania, B. Bjerkehagen, H. O. Ohnstad, H. M. Namlos, J. Wang, B. E. Kristiansen, and O. Myklebost Array Comparative Genomic Hybridization Reveals Distinct DNA Copy Number Differences between Gastrointestinal Stromal Tumors and Leiomyosarcomas. Cancer Res., September 15, 2006; 66(18): 8984 - 8993. [Abstract] [Full Text] [PDF]

				R. Lupu and J. A. Menendez Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators? Endocrinology, September 1, 2006; 147(9): 4056 - 4066. [Abstract] [Full Text] [PDF]

				C.-p. Chuu, R. A. Hiipakka, J. M. Kokontis, J. Fukuchi, R.-Y. Chen, and S. Liao Inhibition of Tumor Growth and Progression of LNCaP Prostate Cancer Cells in Athymic Mice by Androgen and Liver X Receptor Agonist. Cancer Res., July 1, 2006; 66(13): 6482 - 6486. [Abstract] [Full Text] [PDF]

				F. P. Kuhajda Fatty Acid synthase and cancer: new application of an old pathway. Cancer Res., June 15, 2006; 66(12): 5977 - 5980. [Abstract] [Full Text] [PDF]

				Y. Guo, H. Shen, P. Xiao, D.-H. Xiong, T.-L. Yang, Y.-F. Guo, J.-R. Long, R. R. Recker, and H.-W. Deng Genomewide Linkage Scan for Quantitative Trait Loci Underlying Variation in Age at Menarche J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1009 - 1014. [Abstract] [Full Text] [PDF]

				J. Fukuchi, R. A. Hiipakka, J. M. Kokontis, S. Hsu, A. L. Ko, M. L. Fitzgerald, and S. Liao Androgenic Suppression of ATP-binding Cassette Transporter A1 Expression in LNCaP Human Prostate Cancer Cells Cancer Res., November 1, 2004; 64(21): 7682 - 7685. [Abstract] [Full Text] [PDF]

				J. Fukuchi, J. M. Kokontis, R. A. Hiipakka, C.-p. Chuu, and S. Liao Antiproliferative Effect of Liver X Receptor Agonists on LNCaP Human Prostate Cancer Cells Cancer Res., November 1, 2004; 64(21): 7686 - 7689. [Abstract] [Full Text] [PDF]

				K. Kee, S. Vujcic, S. Merali, P. Diegelman, N. Kisiel, C. T. Powell, D. L. Kramer, and C. W. Porter Metabolic and Antiproliferative Consequences of Activated Polyamine Catabolism in LNCaP Prostate Carcinoma Cells J. Biol. Chem., June 25, 2004; 279(26): 27050 - 27058. [Abstract] [Full Text] [PDF]